Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2022 MedTech R&D Spotlight Call Series
Inspire Medical Systems (NYSE: INSP), a leader in medical technology for obstructive sleep apnea (OSA), will participate in the Wells Fargo 2022 MedTech R&D Spotlight Call Series on February 18, 2022, at 10:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Inspire Medical Systems (NYSE: INSP), a leader in medical technology for obstructive sleep apnea (OSA), will participate in the Wells Fargo 2022 MedTech R&D Spotlight Call Series on February 18, 2022, at 10:00 a.m. ET. The presentation will be accessible via a live webcast. Inspire's unique Inspire therapy is the only FDA-approved neurostimulation treatment for moderate to severe OSA, showcasing the company's commitment to innovative solutions. A replay of the presentation will be available for two weeks on Inspire's Investor website.
Details
News Market Reaction – INSP
The recorded move for INSP in the trading session of this news was +1.44%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will be participating in the Wells Fargo 2022 MedTech R&D Spotlight Call Series on February 18, 2022.
Inspire is scheduled to present at 10:00 a.m. Eastern Time. The presentation will be accessible via a live webcast at: https://view.knowledgevision.com/presentation/2c84dae917fb44d88db4a7a37798f38f
A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Investor and Media Contact:
Bob Yedid
LifeSci Advisors
bob@lifesciadvisors.com
646-597-6989
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.